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SUMO isoformon by small ubiquitin-like modiﬁer (SUMO) controls diverse cellular processes
including transcriptional regulation, nuclear transport, cell-cycle progression, DNA repair, and signal
transduction pathway. Sumoylation is a highly dynamic process that is reversed by a family of Sentrin/SUMO-
speciﬁc proteases (SENPs). Thus, desumoylation process must be important for regulation of the fate and
function of SUMO-conjugated proteins as well as SUMOylation process. SENPs catalyze the removal of SUMO
from SUMO-conjugated target proteins as well as the cleavage of SUMO from its precursor proteins. Since the
ﬁrst report of yeast desumoylating enzymes, many studies have revealed the structural and cellular biological
properties of SENP family. This review focuses on the speciﬁcity of the SENPs' catalytic activities with regard
to SUMO isoforms and their emerging roles as cellular regulators.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionUbiquitin (Ub) and ubiquitin-like proteins (Ulps) are covalently
conjugated to target proteins and alter the properties of modiﬁed
proteins [1,2]. SUMO has about 18% identity to Ub in amino acid
sequence and executes a variety of biological functions comparable to
Ub [3–5]; it is involved in the control of gene expression, genomic and
chromosomal integrity, intracellular transport, and protein stability
[6]. The list of proteins subjected to sumoylation is rapidly growing,
and the event of sumoylation is not conﬁned to the nucleus but
occurred in most subcellular compartments [7,8].
SUMO conjugation to target proteins results in the formation of
isopeptide (amide) bond between the C-terminal glycine of SUMO and
the ɛ-amino group of lysine within the target proteins. Similar to
ubiquitination, sumoylation is a dynamic process that can be readily
reversed. Therefore, cellular abundance of particular SUMO-conju-
gated substrates is regulated by a balance between SUMO conjugation
and SUMO deconjugation. Yeast enzymes responsible for SUMO
processing (C-terminal hydrolase activity) and deconjugation (iso-
peptidase activity) are referred to as Ubl-speciﬁc proteases (Ulp)
[9,10]; the Ulp found in humans are referred to as SENPs [11–13].
During SUMO metabolism, Ulp/SENPs catalyze three distinct
processes: processing, deconjugation, and chain editing [14]. Like
ubiquitin, SUMO proteins are expressed as precursor proteins that
carry a C-terminal extension of variable length (2–11 amino acids)
found after a conserved di-glycine motif. To function as a modiﬁer oft tel.: +82 2 880 9078; fax: +82
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l rights reserved.target proteins, the C-terminal di-glycine motif of the SUMO proteins
must be exposed by the action of SUMO speciﬁc protease [2]. SUMO
processing activity of SENPs is responsible for cleavage after the C-
terminal di-glycinemotif and SUMO deconjugating activity of SENPs is
required for the cleavage of amide bond between the C-terminus of
the mature SUMO and the ɛ-amino group of the target lysine within
the substrates. Chain editing refers to the dismantling of SUMO chains.
This review summarizes the recent ﬁndings of substrate speciﬁcity
of SENPs that demonstrate selectivity for the SUMO substrates and the
current knowledge of the biological functions of desumoylating
enzymes as diverse cellular regulators.
2. The SUMO family and SUMO pathway
The budding yeast Saccharomyces cerevisiae expresses one SUMO
ortholog named Smt3 [15]. Inmammals, three SUMO familymembers,
designated SUMO-1, SUMO-2 and SUMO-3 are expressed [16]. The
mature forms of SUMO-2 and SUMO-3 share 97% identity, but have
only a 50% sequence identity with SUMO-1 [1,2,17]. The mature forms
of SUMO-2 and SUMO-3 only differ from one another by three amino-
terminal residues; these two isoforms have sometimes been referred
to interchangeably in the literature. Here, we will refer to the isoform
with two amino acids after the di-glycine motif as SUMO-2 (Gly-Gly-
Val-Tyr) and the one with 11 amino acids as SUMO-3 (Gly-Gly-Val-
Pro-Ser-Ser-Leu-Ala-Gly-His-Ser-Phe). A fourth member of the human
SUMO protein family (SUMO-4) has a predicted 86% amino acid
similarity with SUMO-2, and it has been reported to be expressed
mainly in the kidneys, lymph nodes, and spleen [18]. However, Proline
90 in SUMO-4 appears to inhibit the maturation of precursor of
SUMO-4 and it is unclear whether SUMO-4 is covalently modiﬁed to
target substrates in vivo [19].
Fig. 1. Primary structure of Ulp/SENPs. The conserved domain is shown in the purple
box. The black bars represent the nonconserved variable regions. Note that the catalytic
domains of SENP6 and SENP7 are divided by the insertions.
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terminal di-glycine motif, is activated by the SUMO-activating enzyme
(E1), a heterodimeric protein composed of Uba2 and Aos1 [20–23].
SUMO is then transferred to the catalytic Cys residue of Ubc9, a
conjugationenzyme (E2) [24–27]. Finally, an isopeptidebond is formed
between the C-terminal Gly residue of SUMOand the ɛ-amino group of
a lysine residue in the target protein. At this step, SUMO protein ligase
(E3)helps themodiﬁcation tobemoreefﬁcient.An intriguing featureof
SUMOmodiﬁcation is that target lysine residues areusually located in a
consensus SUMO modiﬁcation motif, ΨKxE/D (where Ψ is a large
hydrophobic residue and x is any amino acid) [2,6,28]. This is
remarkable because such a sequence is lacking in the ubiquitin system.
Ubc9 is capableof recognizing thismotif and transferringSUMOmoiety
to all SUMO substrates [4,28]. However, some SUMO substrates lacking
this motif have been identiﬁed [29,30]. Maybe SUMO E3 ligases
facilitate and increase SUMO modiﬁcation of proteins lacking this
motif. Several SUMO E3 enzymes have been identiﬁed, and the PIAS
family proteins contain a modiﬁed RING domain and bind SUMO non-
covalently [31–36]. The polycomb protein Pc2 and the nucleoporin
RanBP2 also act as SUMO E3 ligases [37–40].
There are several noticeable distinctions between SUMO-1 and
SUMO-2/3. One obvious difference is the presence of a large pool of free
or non-conjugated SUMO-2/3 compared to SUMO-1 in the cell. The
existing nonconjugated pool of SUMO-2/3 can be readily conjugated to
high molecular mass proteins in reaction to stress stimuli such as heat
shock, oxidative stress, and ethanol exposure [41]. In addition,
individual target proteins can be selectively modiﬁed by SUMO-1 and
SUMO-2/3. For example, the Ran GTPase-activating protein (RanGAP) 1,
is preferentially modiﬁed by SUMO-1, but very poorly modiﬁed by
SUMO-2/3 [41]. Interestingly, SUMO-2 and SUMO-3 have consensus
SUMOmodiﬁcationmotif in the N-terminal region (Lys11), but SUMO-1
does not [11,12,42]. An internal sumoylation site is also found in Smt3
(Lys15). Thus, analogous to Ub conjugation, SUMO-2 and SUMO-3, as
well as the yeast Smt3, can form polymeric SUMO chains [42,43]. Poly-
SUMO chains are detected in S. cerevisiae; however, SUMO chain
formation has been shown not to be a major feature of SUMO function
in yeast, either for production of the most abundant conjugates or for
the activities required for yeast viability and stress resistance [44].
In higher eukaryotes, the importance of poly-SUMO chains for the
regulation of target proteins has been suggested. Elimination of SUMO-3
protein by siRNA causes destabilization of promyelocytic leukaemia
(PML) localization in thenucleus, indicatinga crucial role forpolySUMO-
3 chain formation in the nuclear body (NB) dynamics [45]. In contrast to
ubiquitination, SUMO modiﬁcation does not usually trigger protein
degradation; the action of SUMO as an inhibitor of ubiquitin-mediated
degradation iswell documented. IκBα, Smad4,Huntingtin, PCNA,Rad52,
HIF-1α and Mdm2 are well-known examples of substrates that escape
from degradation by the protection of SUMO [7,46–53]. However, the
results of recent studies in yeast and in human cells have suggested that
polymeric SUMO chains (polysumoylation) play a role in the promotion
of ubiquitin-mediated proteasomal targeting [54,55]. Theﬁrst identiﬁed
protein degraded by polysumoylation-dependent polyubiquitination
was reported to be PML. Increase of polymeric SUMO-2 modiﬁcation of
PML by arsenic trioxide (ATO, As2O3) treatment has been shown to lead
to its subsequent polyubiquitination by RNF4, ubiquitin E3 ligase
followed by efﬁcient degradation [56,57]. Polysumoylation of BMAL1
with the SUMO-2/3 moiety serves as a targeting signal for its
ubiquitination and proteasomal degradation in vivo [58]. It appears
that, as in the case of ubiquitin, monomeric and polymeric chains of
SUMO proteins have distinct biological functions.
3. Desumoylating enzymes — Ulp/SENPs
In budding yeast, two Smt3-speciﬁc proteases, Ulp1 and Ulp2, have
been characterized [9,10]. The similarity between Ulp1 and Ulp2 has
been conﬁned primarily to a protease domain of ∼200 amino acidsreferred to as the Ulp domain (UD) [9]. Database searches initially
identiﬁed eight genes for human proteins with signiﬁcant sequence
similarity to the C-terminal Ulp domain of yeast Ulp1 that were
believed to be SUMO-speciﬁc proteases (SENP1–8) (Fig. 1) [59]. Later,
SENP3 and SENP4 turned out to be the same proteins. Not all SENPs
are SUMO-speciﬁc; indeed SENP8 (also called NEDP1 or DEN1) has
speciﬁcity toward another small ubiquitin-like protein, NEDD8
[60,61]. At present, six true human SENPs can be divided into two
groups. SENP1, SENP2, SENP3, and SENP5 are most closely related in
sequence to Ulp1, whereas SENP6 and SENP7 are related to Ulp2
[11,62]. SENP6 and SENP7 contain an additional insertion that splits
the conserved catalytic domain, but the function of this inserted
sequence remains to be identiﬁed [12,63].
Ulp/SENPsarecysteineproteases thatcontainaconservedC-terminal
domain with the characteristic His-Asp-Cys catalytic triad. These
enzymes belong to the clan CE proteases and theirmechanistic relatives,
deubiquitinatingenzymes (DUBs), are classiﬁed to the clanCAofpapain-
like proteases [64]. From the viewpoint of the closely related sequences
between theUb andSUMOconjugationpathwayenzymes (E1 andE2), it
is surprising to ﬁnd that there are no sequence similarities between Ub
and SUMO deconjugating enzymes [64]. There have been developed
many biochemical assays to determine the UBL speciﬁcities of the UBL
isopeptidases [65–69]. Those studies will be very helpful for character-
izing a novel modulator of isopeptidase activity and screening useful
drugs for UBL isopeptidase-related diseases.
The non-conserved N-terminal regions of the Ulp/SENPs are
thought to determine the subcellular localization and substrate
speciﬁcity of each protease. Ulp1 has been detected at the nucleo-
plasmic face of the nuclear pore complex (NPC) [9,70,71], and Ulp2 is
present in the nucleoplasm [9]. The non-conserved N-terminal
domain of Ulp1 is necessary for the correct localization of Ulp1 at
the nuclear envelope [70]. Remarkably, N-terminal deleted Ulp1, but
not full-length Ulp1, suppresses the cellular defects of ulp2Δ mutant
cells and substantially reduces Smt3-protein conjugates. The non-
catalytic N-terminal domain of Ulp1 functions as a physiologically
signiﬁcant restraints with regard to the subset of sumoylated proteins
which are natural targets of nucleoplasmic Ulp2. Subcellular localiza-
tion of Ulp/SENPs is, at least in part, an important constraint of SUMO
isopeptidase speciﬁcity [70].
SENP1 contains both N-terminal localization signals (NLS) and
nuclear export signals (NES), but the primary location of SENP1 is in
the nucleus [13,72,73]. In CV-1 cells, GFP-SENP1 was localized mainly
in the cytoplasm but relocalized into the nucleus after Leptomycin B
(LMB) treatment, indicating the nucleo-cytoplasmic shuttling of
SENP1. Upon HIPK2 co-expression, GFP-SENP1 was translocated into
Fig. 2. Catalytic functions of desumoylating enzymes. (A) Processing of SUMO
precursors by Ulp/SENPs generate free SUMO monomers that are ready for protein
modiﬁcation. (B) Reversal of SUMO conjugation occurs by deconjugation of SUMO from
modiﬁed proteins. (C) Ulp/SENPs function in the editing of SUMO at the distal ends of
poly-SUMO-2/3 chains conjugated to protein substrates. The red circle represents
SUMOs and the pink circle represents SUMO-2/3.
Table 1
Ulp/SENPs localization and substrate speciﬁcity of catalytic activity
Name Subcellular localization Processing Deconjugation Chain
editing
Saccharomyces cerevisiae
Ulp1 Nuclear periphery Yes Yes No
Ulp2 Nucleoplasm No No Yes
Humans
SENP1 Nuclear speckled foci,
nuclear pore
SUMO-1NSUMO-
2NSUMO-3
SUMO-1/2/3 No
SENP2 Nuclear pore SUMO-2NSUMO-
1NSUMO-3
SUMO-1/2/3 No
SENP3 Nucleolus Unknown SUMO-2/3 No
SENP5 Nucleolus SUMO-3 SUMO-2/3 No
SENP6 Nucleoplasm No (very low) SUMO-1 SUMO-2/3
SENP7 Nucleoplasm No (very low) No (very low) SUMO-2/3
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the extracellular signaling pathways with concurrent post-transla-
tional modiﬁcations such as sumoylation or phosphorylation, though
any data that can prove the hypothesis has not yet been reported [74].
SENP2 is closely related to SENP1; it is primarily found in the nuclear
envelope in association with the NPC [75,76]; it also accumulates in
distinct subnuclear bodies [77]. It has been reported that SENP2 has
both NLS and NESwithin its non-conserved N-terminus. Using a series
of SENP2 mutants and interspecies heterokaryon assay, it has been
shown that SENP2 shuttles between the nucleus and the cytoplasm
and that the shuttling is blocked by mutations in the NES or by LMB
treatment. Interestingly, the SENP2 in the cytoplasm is efﬁciently
polyubiquitinated and triggered to be degraded by the 26S protea-
some pathway [78]. In addition, alternative mRNA splicing generates
at least three different SENP2 isoforms with strikingly distinct cellular
localization (Axam, SMT3IP2/Axam2, SuPr-1). Axam localizes to the
nucleoplasmic face of the NPC [76], and Axam2 and SuPr-1 have been
detected in the cytosol and PML bodies [79,80]. This pattern of isoform
localization underscores the notion that a distinct subcellular
distribution might contribute to the substrate speciﬁcity of the Ulp/
SENPs. SENP3 and SENP5 are detected predominantly in the nucleolus
[81,82]. Very recently, it has been reported that SENP3 is destabilized
in a nucleolar protein nucleophosmin (NPM1)-dependent manner by
a process involving sequential p19Arf-induced SENP3 phosphorylation,
polyubiquitination and raid proteasomal degradation [83]. SENP6 was
originally reported to be located in the cytoplasm [84], but recent
reports suggest that it is located in the nucleus [62,85]. Recently
identiﬁedmouse SUSP4 has been found to be closely related to human
SENP2, and was detected predominantly in the nuclear fractions.
SUSP4 has been shown to be ubiquitously expressed, at varying levels,
in different tissues and cell lines [48].
4. Catalytic mechanism of desumoylating enzymes
There have been many structural and biochemical investigations
of Ulp/SENPs to identify their speciﬁcity for SUMO isoforms, inaddition to the differentiation among processing, deconjugation and
chain editing reactions (Fig. 2 and Table 1). Crystal structures of
several Ulp/SENPs have revealed that these proteases have narrow
and tight active site tunnels for di-glycine motif recognition and
utilize conserved tryptophans to clamp down on the C-terminal di-
glycine motif of SUMO within a hydrophobic channel [5,86,87]. Clan
CA protease DUBs also contain a restricted tunnel for the two Gly
residues at the C-terminus of ubiquitin [88,89]. And each family
contains size dominant exosite that binds epitopes on the Ub or
SUMO surface, respectively. By substrate positional scanning proﬁle
Drag et al. determined the optimal cleavage motif for SENPs (except
SENP3) and several DUBs [14,90]. Not surprisingly, SENP1, 2, and 5
showed optimal preferences for the SUMO C-terminal tetrapeptide
sequence QTGG and DUBs for the LRGG sequence corresponding to
the Ubiquitin C-terminus. Surprisingly, SENP6 and 7 prefer the LRGG
sequence. However, none of the known LRGG-containing natural
substrates was processed by SENP6 and 7. Interestingly, in contrast to
the wide conformation changes and catalytic site reordering of DUBs
upon Ub binding, catalytic domains of desumoylating enzymes did
not undergoes large conformational changes for complex formation
with SUMO [64,87].
Ulp1 and Ulp2 have distinct and non-redundant catalytic activity.
A large amount of mature Smt3weakly rescues the lethal course of the
ulp1Δmutant cells, but full-length Smt3 does not [10]; these ﬁndings
suggest that Ulp1 plays an important role in Smt3 processing. By
contrast, it appears that Ulp2 is specialized for chain editing activities.
In yeast, mutants lacking Ulp2 accumulated high molecular weight
SUMO-containing species only in the presence of wild-type Smt3;
however, this was not the case in the smt3 mutants that did not have
the critical lysine residues [44]. Further, Smt3 branch-site mutants
suppressed several phenotypes of ulp2Δ, indicating that such defects
arise from Smt3-chain accumulation [44].
Recently, structures have been determined for the catalytically
inert form of SENP1 and the SENP2 catalytic domain, in complexes
with actual substrate-SUMO precursors and SUMO-modiﬁed Ran-
GAP1 [91,92]. In both cases, the scissile peptide bond is kinked at a
right angle to the C-terminal tail of SUMO-1 due to a cis arrangement
of the amide nitrogens. As a result of this structure, it is cleared that a
kinked, cis conﬁguration for the scissile bond is crucial for the cleavage
of both peptide and isopeptide bonds. SENP1 has both C-terminal
hydrolase and isopeptidase activities and, although it does not
discriminate among SUMO isoforms during deconjugation, it is
strongly isoform speciﬁc during SUMO protein processing [86,93].
SENP1 processes SUMO-1 in preference to SUMO-2, but shows limited
activity with regard to SUMO-3. The histidine residue immediately
after the di-glycine motif of SUMO-1 confers rapid processing by
SENP1 in vitro and Pro94 in SUMO-3 is responsible for the resultant
slow processing [93]. The Kmvalues for SUMO-1 and SUMO-3 cleavage
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lower than that for SUMO-1. Therefore, the ability of SENP1 to
differentially cleave SUMO-1 over SUMO-3 is not a consequence of
preferential binding of substrate, but rather is based on a more
efﬁcient catalytic process [91]. This may result from the differences in
the ability of SENP1 to kink the scissile bonds in SUMO-1 and SUMO-3.
In the cis amide conformation, the side chain of His98 of SUMO-1
forms a hydrogen bond to the Gly600 of SENP1. However, the proline
residue in SUMO-3 is likely to have an inhibitory effect on the
orientation of the scissile peptide bond due to its rigid structure [91].
SENP2 can deconjugate RanGAP1-SUMO-1, RanGAP1-SUMO-2 and
RanGAP1-SUMO-3 with similar efﬁciency, but shows different sub-
strate preferences during processing. SENP2 processes SUMO-2 more
efﬁciently than SUMO-1, but processes SUMO-3 poorly as with SENP1
[87]. The SENP2 structures reported by Reverter et al., showed that in
both productive processing (SENP2-pre-SUMO-3) and deconjugation
(SENP2-RanGAP1-SUMO) complexes, the scissile peptide bond is
coordinated by a protease hydrogen bond network formed by the
SENP2 Val477 and Gln542 side chain, which stabilizes a 90° kink in the
substrate, directing residues on the C-terminal side of the scissile bond
toward a protease surface composed of SENP2 Trp420, Val477, Gly545
and Met474. This geometry appears to be unfavourable for the
processing SUMO precursors; the side chains on the C-terminal side of
the cleavage site present a steric impediment for interaction with the
SENP2 surface. This explains why SENP2 acts more efﬁciently in
deconjugation than in processing [92].
SENP5 displays both C-terminal hydrolase and isopeptidase
activities. SENP5 shows SUMO-3 C-terminal hydrolase activity, but
does not process SUMO-1 in vitro. In addition, SENP5 demonstrates
isopeptidase activity with SUMO-2 and SUMO-3 conjugates but not
against SUMO-1 conjugates in vivo [82,94]. SENP3 displays speciﬁcity
for SUMO-2 and SUMO-3 conjugates, but not for SUMO-1 [82,95].
SENP6 has a special role in the dismantling of highly conjugated
SUMO-2 and SUMO-3. SiRNA-mediated depletion of SENP6 suggests
that it might function to accurately maintain nuclear structures,
particularly PML bodies [62]. In addition, it has also been reported that
SENP6 has isopeptidase activity with regard to a single SUMO moiety.
SENP6 speciﬁcally removes SUMO-1 from retinoid X receptor (RXR)α,
but not from androgen receptor (AR) or peroxisome proliferator-
activated receptor (PPAR) γ [85]. Recently, the structure of the SENP7
catalytic domain (662 to 984) has been characterized by Lima and
Reverter [95]. Using biochemical assays they demonstrated that
SENP6 and SENP7 have excellent deconjugating activity for poly-
SUMO-2/3 chains. Structural analysis has shown that SENP7 catalytic
domain contains four Loops unique to the SENP6/7 subfamily of Ulp/
SENP family members. Val713 is positioned in SENP6 and SENP7
immediately adjacent to Loop-1, whereas this residue was substituted
by glutamate in SENP1 and SENP2. Removal of these features by Loop-
1 deletion or Glu substitution for Val diminishes SENP7 activity with
regard to poly SUMO-2/3 chains. These unique determinants within
the SENP6/7 subfamily appear to contribute to the deconjugation of
poly-SUMO chains [95]. According to the activity proﬁling of human
SENPs using recombinant catalytic domains of SENPs (SENP3 is
omitted owing to difﬁculties in obtaining sufﬁcient soluble protein),
SENP1 was found to be the most efﬁcient C-terminal hydrolase, but it
has substantially higher isopeptidase activity compared to C-terminal
hydrolase activity [96]. This suggests that SENP1 might be the most
active SUMO hydrolase in vivo.
5. Desumoylating enzymes in plants and parasitic protozoa
A database search, as well as genetic and biochemical analyses,
revealed that components of the SUMO conjugation and deconjuga-
tion systems are conserved in plants such as Arabidopsis, rice, tomato,
and Medicago [97]. In plants, sumoylation has been implicated in
phosphate starvation responses, cold tolerance, basal thermotoler-ance, pathogen defence, and regulation of ﬂowering time. To date, four
Arabidopsis SUMO proteases have been characterized functionally
[98]. All of them have SUMO precursor protein processing and
substrate deconjugation activity. Signiﬁcantly, they display SUMO
isoform speciﬁcity and discriminate between processing and
deconjugation.
By literature and BLASTP homology searches Ponder and Bogyo
made a comprehensive list of homologs of known Ubls and Ubl-
deconjugating enzymes in medically important parasitic protozoa
[99]. Similar to yeast, most of the organisms examined have a single
SUMO homolog. And of the parasites surveyed, one or two homologs
of the essential yeast desumoylating enzyme Ulp1 were found.
6. Role of desumoylating enzymes in biological pathways
Desumoylating enzymes are involved in the regulation of SUMO-
dependent pathways by balancing the sumoylation status of target
proteins. Ulp/SENPs participate in diverse biological pathways
including transcriptional regulation, development, cell growth and
differentiation, cancer, and ribosome biogenesis.
6.1. Transcriptional regulation
More than 120 mammalian SUMO substrate proteins have been
identiﬁed. Two thirds of them are transcription factors and co-
regulators [7,100]. In some cases, SUMO modiﬁcation enhances the
activity of transcription activators and co-activators; however, the
majority of this modiﬁcation is biased towards the enhancement of
the inhibitory effects on transcription by the transcription factors and
co-regulators. Therefore, desumoylation activity of Ulp/SENPs plays an
important role in the derepression of the inhibited transcription by
SUMO modiﬁcation. SENP1 relieves the SUMO-dependent repression
of AR, p300, Ets1, Reptin, and KAP1 [101–105]. Enhancement of AR-
dependent transcription is not mediated by desumoylation of AR, but
rather is processed by the deconjugation of histone deacetylase 1
(HDAC1), thereby reducing its deacetylase activity [104]. The action of
SENP1, on c-Jun transcription, is mediated by the derepression of p300
by SUMO removal [105]. Desumoylation of Reptin by SENP1
signiﬁcantly attenuates binding to HDAC1 and induces the expression
of the metastasis suppressor gene KAI1 [102]. SUMO removal of KAP1
by SENP1 increases the basal phosphorylation of KAP1 on Serine 824
site, which stimulates transcription of p21 and Gadd45α [101]. SUMO
cleavage by SENP2 (SuPr-1) potentiates transcriptional activation of
Sp3 and changes the subcellular localization of Sp3 [77]. Although
SENP2 has been isolated as a c-Jun activator, c-Jun is not a direct target
of SENP2. Instead, PML plays a major role in the SENP2 action on gene
transcription. Coactivators kept in the PODs by PML were reported to
be released by SENP2 binding to SUMO-conjugated PML [80].
SMT3IP2/Axam2, the mouse homolog of SENP2, negatively regulates
the Wnt signaling pathway by promoting the degradation of β-
catenin. However, this function of Axam2 is independent of its
protease activity, and the involvement of Axam2 in Wnt signaling
remains to be further elucidated [79]. MEF2, a transcriptional activator
of muscle differentiation, is also a SUMO target. SENP3 reverses the
modiﬁcation to augment the transcriptional and myogenic activities
of MEF2 [106]. The isopeptidase activity of SENP6 acts on RXRα, but
not on AR and PPARγ, and increases the RXR transcriptional activity
[85].
6.2. Development
The characterization of a random retroviral insertional mutation in
the mouse ortholog of SENP1 highlights the critical importance of
regulating the levels of sumoylation during mouse embryogenesis,
which suggests a non-redundant and essential role for SENPs during
development [107]. A signiﬁcant reduction in the SENP1 expression
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element; this mutation reduces both deconjugation and processing of
SUMO-1. The physiological consequences of the loss of SENP1 function
during mouse development are apparent after midgestation in the
placenta. These abnormalities result in placental abnormalities
incompatible with embryonic development.
6.3. Growth and differentiation
In yeast, Ulp1 is essential for the G2/M cell cycle transition, but
Ulp2 is not essential for cell cycle progression [5,10,36]. Ulp2 mutants
show the reduction of chromosome stability, temperature sensitive
growth and increased sensitivity to agents that cause DNA damage
[9,108]. Recently, it has been reported that Ulp2 is required for
resumption of cell division following termination of the DNA damage
checkpoint, although it was not required for DNA double-strand
breakage repair. When non-repairable DSB was introduced by HO
endonuclease, Ulp2 deletion mutants activated and maintained a
normal DNA damage checkpoint arrest, and then terminated
checkpoint signaling; then a large fraction of these mutants caused
arrest at post-metaphase [109]. The Ulp2-H531A catalytic-site mutant
demonstrates permanent arrest after DNA damage similar to ulp2
deletion mutant, suggesting that one or more proteins sumoylated
following checkpoint activation interfere with the successful comple-
tion of mitosis. Notably, the cell growth defects in Schizosaccharo-
myces pombe ulp1 mutants were not rescued by overexpression of the
mature form of Pmt3. This suggests that the deconjugating activity of
Ulp1 or the desumoylation of some substrates is required for normal
cell cycle progression [110].
It has been shown that increased levels of SUMO-1 in synovial
ﬁbroblasts (SFs), from patients with RA (arthritis), contribute to the
resistance of these cells to Fas-induced apoptosis. This phenotype was
conferred by increased sumoylation of nuclear PML, and increased the
recruitment of the pro-apoptotic molecule Daxx to PML NBs. SENP1
can reverse the apoptosis-inhibiting effects of SUMO-1 by releasing
Daxx from PML-NBs [111]; in addition, it is expressed at a lower level
in the RA-SFs. This ﬁnding suggests that SENP1 may contribute to the
pathogenesis of inﬂammatory diseases such as RA. Mammalian NAD+-
dependent histone deacetylase SIRT1 deacetylates and inactivates
apoptotic proteins such as p53. SIRT1 is a SUMO modiﬁcation target;
SUMOylated SIRT1 is active and suppresses the activity of its apoptotic
substrates. SENP1 promotes apoptosis in cells exposed to genotoxic
stress by interacting and desumoylating SIRT1 [112]. The critical role
of SENP1 in TNFα-induced ASK1-JNK activation and endothelial cell
apoptosis is conferred by the translocation of SENP1 from cytoplasm
to the nucleus in response to TNF [113]. In the nucleus, SENP1
mediates desumoylation and translocation of HIPK1 to the cytoplasm,
leading to enhanced ASK1-JNK dependent apoptosis. Recently, it has
been demonstrated that SENP5 is required for mammalian cell
division [94,114]. Knockdown of SENP5 by RNAi leads to a dramatic
decrease in HeLa cell proliferation and the appearance of many cells
with multiple nuclei and aberrant nuclear morphology, in particular a
multilobular morphology, indicative of defects in mitosis and
cytokinesis.
6.4. Cancer and other diseases
There are some reports on desumoylating enzymes and tumor-
igenesis. SENP1 has been upregulated over two fold in thyroid
oncocytic tumors using a two-step differential RT-PCR assay [115]. In
addition, it has been reported that SENP1 is overexpressed in human
prostate cancer specimens. Transgenic expression of SENP1 in mouse
prostate epithelium leads to the development of early neoplastic
lesions in the prostate [116]. However, SENP1 expression has been
shown to be reduced inmetastatic cancer cell line, LNCaP, compared to
RWPE1 normal prostate epithelial cell line [102]; these ﬁndingssuggest that the contribution of desumoylating enzymes in cancer
development and metastasis appear to be different [117]. Constitu-
tional t(12;15)(q13;q25) translocation between SENP1 and MESDC2
(embryonic polarity-related mesoderm development gene 2) that
disrupts both genes was identiﬁed from a human patient with
infantile sacrococcygeal teratoma [118]. A chimeric SUSP1-T cell
lymphoma breakpoint associated target (TCBA) 1 gene, located at
chromosome band 6q21, in T-cell lymphoblastic lymphoma cell line
HT-1, has been identiﬁed [119]. This chimeric mRNA expresses a
truncated SUSP1 after nucleotide 550 due to a frameshift at TCBA1 in
exon 4. Altered subcellular localization of SENP5 in patients with oral
squamous cell carcinoma (OSCC) has been reported. SENP5 predomi-
nantly localized to the cytoplasm of OSCC and SENP5 expression was
associated with differentiation of OSCC cells [120]. These ﬁndings
implicate a possible role for SENP family in cancer development.
6.5. RNA biogenesis
There have been several studies demonstrating the effects of
sumoylation/desumoylation on proteins potentially involved in RNA
metabolism. Ulp1 is genetically linked to the 60S export factor Mtr2,
and plays an important role in 60S pre-ribosome particle export [121].
Ulp1 has been localized primarily to the nuclear pore complex (NPC)
via its interaction with the two karyopherin nuclear transport factors
Kap121 (Pse1) and Kap60–Kap95 [71]. The ﬁlamentous proteins Mlp1
and Mlp2 and the nucleoporin Nup60 have also contributed to the
localization of Ulp1 [122,123]. Mlp1, Mlp2 and Nup60 are involved in a
RNA quality-control pathway that prevents leakage of improperly
processed mRNA from the nucleus. Esc1 is a non-NPC nuclear
envelope protein that controls the proper assembly of the nuclear
basket. Loss of Esc1 results in the retention of unspliced pre-mRNA in
the nucleus, and Esc1 modulates Ulp1 localization at the nuclear
envelope. Ulp1 is also required for normal nuclear pre-mRNA
retention by a mechanism genetically linked to Esc1 and Mlp1 [122].
Thus, it is possible that the strategic localization and the activity of
Ulp1, at the NPC, allows for surveillance of mRNA export during
nuclear export.
It has been reported that two proteins involved in the pre-mRNA 3′
processing, CPSF-73 and symplekin are sumoylated. SENP2 interacts
with these proteins and inhibits 3′ processing in HeLa nuclear extracts
in vitro [124]. However, whether SENP2 inﬂuences 3′ processing in
vivo requires further investigation. Recently, SENP3 has been shown to
be crucial for 32S rRNA processing in the nucleolus [125]. NPM1 is
required for the processing of the 32S rRNA species to mature 28S
rRNA. SENP3 cleaves SUMO-2 from NPM1 and this process is a critical
step for 28S maturation in the nucleolus. The related nucleolar SUMO
protease, SENP5, is unable to deconjugate SUMO-2 from NPM1 and
does not affect 32S processing. However, knockdown of SENP5
reduces the amount of the primary 47S rRNA transcript, indicating
that SENP3 and SENP5 play a role in ribosome biogenesis by acting on
distinct substrates [125]. Another group suggested new SENP3 and
SENP5 targets for their role in ribosome biogenesis [126]. SENP3 and
SENP5 codepletion enhanced the 60S ribosomal subunit RPL37A and
60S pre-ribosomal export factor GNL2 sumoylation. They speculated
that NPM1 acts an adaptor for targeting of SENP3 and SENP5 to
ribosomal proteins.
6.6. Chromosome maintenance
Yeast Ulp2 is required for the maintenance of chromosome
structures. Ulp2Δ mutant strains are impaired in the mitotic-speciﬁc
targeting of the condensin complex to chromatin, in particular rDNA
chromatin [108]. In addition, Ulp2 mutants display an increase in
premature separation and fail to maintain cohesion at the regions
proximal to centromere, which is caused in part by the poor regulation
of the SUMO modiﬁcation status of DNA Topoisomerase II (Top2)
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modiﬁcation of proteins involved in organizing centromeric chroma-
tin into a structure that supports the centromere cohesion dynamics.
Precocious Dissociation of Sisters gene (Pds5p) is important for sister
chromatid cohesion; Ulp2 overexpression efﬁciently suppresses the
temperature sensitivity and precocious sister dissociation in pds5
mutants [128]. Pds5p sumoylation promotes the dissolution of
cohesion and Ulp2 activity modulates this sumoylation. Recently, it
has been shown that inactivation of Ulp2 weakens condensin
association with the kinetochore [129].
6.7. Others
Murine SUSP4, which is closely related to human SENP2, has been
found in association with p53 and Mdm2 in vivo. SUSP4-mediated
desumoylation of Mdm2 promotes self-ubiquitination activity of
MDM2 and its destabilization, thereby leading to p53 stabilization
[48]. The expression of SUSP4 is induced by UV damage, but not by
other DNA-damaging agents, such as etoposide and camptothesin,
suggesting that SUSP4 responds to a limited range of stress.
Using SENP1 knockout mice, Cheng et al. demonstrated the
important physiological role of SENP1 in the hypoxic response, and
identiﬁed SENP1 as the speciﬁc isopeptidase that removes SUMO from
HIF1α [130]. SENP1 knockout embryos show severe fetal anemia
caused by reduction in the erythropoietin (Epo) production that
results in early embryonic lethality. SENP1 was found to control Epo
production by regulating the stability of HIF1α during hypoxia. HIF1α
is rapidly degraded in SENP1 knockout mouse embryonic ﬁbroblasts
even under hypoxic conditions, whereas restoration of SENP1
markedly enhanced HIF1α activity. Hypoxia-induced sumoylation of
HIF1α, which promotes its binding to an ubiquitin ligase, von Hippel–
Lindau (VHL) protein, in a proline hydroxylation-independent
manner, leads to its ubiquitination and degradation. SENP1 deconju-
gates sumoylated HIF1α and allows HIF1α to escape from degradation
under hypoxic conditions [130].
The role of SENPs has expanded to include the regulation of
mitochondrial dynamics [131]. The cytosolic pool of SENP5 plays a role
in the regulation of mitochondrial morphology, at least in part, by its
effects on the mitochondrial ﬁssion GTPase DRP1 desumoylation.
Silencing of SENP5 results in a fragmented and altered morphology of
mitochondria and signiﬁcant increases in the production of free
radicals, suggesting a role for SENP5 inmitochondrial morphology and
metabolism [131].
SENPs have been shown to operate at the plasma membrane
controlling ion channel function. The voltage-gated potassium
channel Kv1.5 has been identiﬁed as a target of SUMO and SENP2
leads to a selective hyperpolarization shift in the voltage dependence
of steady-state inactivation [132]. SUMO modiﬁcation silences the
leakage at the K+ channel K2P1 and removal of SUMO by SENP1
overexpression increases the K2P1 channel activity in Xenopus oocytes
[133].
7. Concluding remarks
The list of characterized desumoylating enzymes appears to be
short considering the large number of target proteins that are
modiﬁed by SUMO. In the ubiquitin system, there are ﬁve classes of
deubiquitinating enzyme (DUB) families: four are cysteine proteases
and only one is metalloprotease family. The human genome encodes
approximately 100 putative DUBs [134]. In yeast, at least 17 DUBs have
been identiﬁed by virtue of the conserved catalytic domains. Although
they have been identiﬁed over several decades, new DUBs continue to
be reported and it is unclear how many desumoylating enzymes
remain to be identiﬁed. Even though the substrate speciﬁcity of Ulp/
SENPs is dictated by the subcellular localization of each protease, there
is very speciﬁc substrate recognition in some cases. The nonconservedN-terminal regions of the Ulp/SENPs can provide limited and selected
substrate speciﬁcity by targeting the protease to unique subcellular
compartments or the direct recognition of substrates. To get more
important information about the substrate recognitions by Ulp/SENPs,
information of crystal structures of them will be helpful. Although
many SUMO targets are in the nucleus, it is clear that sumoylation
takes place in all areas of the cell. Some SENPs can be found in areas
that are not their main territory; however, SENPs aremainly located in
the nucleus-associated organelles. How are the proteins sumoylated
outside of the nucleus regulated by desumoylating enzymes? Are they
regulated by the shuttling of SENPs in the cell? How the shuttling is
regulated? The modiﬁcation of these enzymes or the speciﬁc binding
partners might be important to the regulation of these enzymes; or
perhaps new cytosolic desumoylating enzymes might be active in
different locations. The regulatory mechanisms of Ulp/SENPs also
require further elucidation, and the attempt to answer these questions
will be the subject of future investigations.
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